RU2012108173A - Терапевтические арил-амидо-арильные соединения и их применение - Google Patents

Терапевтические арил-амидо-арильные соединения и их применение Download PDF

Info

Publication number
RU2012108173A
RU2012108173A RU2012108173/04A RU2012108173A RU2012108173A RU 2012108173 A RU2012108173 A RU 2012108173A RU 2012108173/04 A RU2012108173/04 A RU 2012108173/04A RU 2012108173 A RU2012108173 A RU 2012108173A RU 2012108173 A RU2012108173 A RU 2012108173A
Authority
RU
Russia
Prior art keywords
aaa
independently represents
olr
compound according
saturated aliphatic
Prior art date
Application number
RU2012108173/04A
Other languages
English (en)
Russian (ru)
Inventor
Джонатан Патрик Томас КОРКОРАН
Саркис Баррет КАЛИНДЖАН
Алан Дэвид БОРТВИК
Дэвид Реджинальд АДАМС
Джейн Тереза БРАУН
Дэвид Мишель Эдриен ТАДДЕЙ
Джейсон Джон ШИРЗ
Original Assignee
Кинг'С Колледж Лондон
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Кинг'С Колледж Лондон filed Critical Кинг'С Колледж Лондон
Publication of RU2012108173A publication Critical patent/RU2012108173A/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/84—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/67—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/75—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/56—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
RU2012108173/04A 2009-09-01 2010-09-01 Терапевтические арил-амидо-арильные соединения и их применение RU2012108173A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0915196.0 2009-09-01
GBGB0915196.0A GB0915196D0 (en) 2009-09-01 2009-09-01 Therapeutic compounds and their use
PCT/GB2010/001650 WO2011027106A1 (en) 2009-09-01 2010-09-01 Therapeutic aryl-am i do-aryl compounds and their use

Publications (1)

Publication Number Publication Date
RU2012108173A true RU2012108173A (ru) 2013-10-10

Family

ID=41202973

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2012108173/04A RU2012108173A (ru) 2009-09-01 2010-09-01 Терапевтические арил-амидо-арильные соединения и их применение

Country Status (15)

Country Link
US (2) US20120149737A1 (cg-RX-API-DMAC7.html)
EP (1) EP2473479A1 (cg-RX-API-DMAC7.html)
JP (1) JP5778675B2 (cg-RX-API-DMAC7.html)
CN (1) CN102639487A (cg-RX-API-DMAC7.html)
AU (1) AU2010291056B2 (cg-RX-API-DMAC7.html)
BR (1) BR112012004173A2 (cg-RX-API-DMAC7.html)
CA (1) CA2771097C (cg-RX-API-DMAC7.html)
GB (1) GB0915196D0 (cg-RX-API-DMAC7.html)
IL (1) IL218137A (cg-RX-API-DMAC7.html)
MX (1) MX2012002481A (cg-RX-API-DMAC7.html)
NZ (1) NZ598331A (cg-RX-API-DMAC7.html)
RU (1) RU2012108173A (cg-RX-API-DMAC7.html)
SG (1) SG178480A1 (cg-RX-API-DMAC7.html)
WO (1) WO2011027106A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201201287B (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0915196D0 (en) 2009-09-01 2009-10-07 King S College London Therapeutic compounds and their use
EP2685972A4 (en) * 2011-03-14 2014-08-13 Io Therapeutics Inc TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES WITH RAR ALPHA SELECTIVE AGONISTS
CN102727475B (zh) * 2012-06-14 2014-05-07 合肥博太医药生物技术发展有限公司 视黄酸及其衍生物在制备防治老年痴呆药物中的应用
CN107207488B (zh) * 2014-12-17 2020-11-17 伦敦皇家学院 作为视黄酸受体β(RARβ)激动剂的双环杂芳基-杂芳基-苯甲酸化合物
WO2016144976A1 (en) * 2015-03-09 2016-09-15 Kings College London Combination therapy with rar alpha agonists for enhancing th1 response
WO2017066428A1 (en) 2015-10-13 2017-04-20 H. Lee Moffitt Cancer Center & Research Institute, Inc. Brd4-kinase inhibitors as cancer therapeutics
US20190112272A1 (en) * 2016-04-07 2019-04-18 High Force Research Limited Synthetic retinoids for use in rar mediated conditions
CN107459519A (zh) 2016-06-06 2017-12-12 上海艾力斯医药科技有限公司 稠合嘧啶哌啶环衍生物及其制备方法和应用
CA3124039A1 (en) * 2018-12-19 2020-06-25 King's College London Immunotherapeutic methods and compositions
GB201900687D0 (en) 2019-01-17 2019-03-06 King S College London Immunotherapeutic methods and compositions
CA3128032A1 (en) 2019-01-29 2020-08-06 The Johns Hopkins University Small molecule neutral sphingomyelinase 2 (nsmase2) inhibitors
US12540121B2 (en) 2019-06-28 2026-02-03 Arizona Board Of Regents On Behalf Of Arizona State University Compositions comprising a retinoid X receptor (RXR) agonist, a retinoic acid receptor (RAR) agonist, or a dual RXR/RAR agonist
JP2026500298A (ja) 2022-12-15 2026-01-06 シンジェンタ クロップ プロテクション アクチェンゲゼルシャフト 殺有害生物剤として有用である新規な二環式カルボキサミド化合物

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2260118C2 (de) 1972-12-08 1982-06-03 Bayer Ag, 5090 Leverkusen Penicilline sowie ihre Verwendung als Arzneimittel
EP0170105B1 (en) 1984-07-07 1990-10-17 Koichi Prof. Dr. Shudo Benzoic acid derivatives
JPS61233678A (ja) 1985-04-09 1986-10-17 Maruko Seiyaku Kk ベンジルピペラジン誘導体
JPS62215581A (ja) 1986-03-18 1987-09-22 Koichi Shiyudo フラボンカルボン酸誘導体
US4808631A (en) 1986-11-07 1989-02-28 Hoffmann-La Roche Inc. Aromatic acid derivatives
US4992468A (en) 1989-07-26 1991-02-12 Allergan, Inc. Phenylethenyl compounds having retinoid-like activity
AU7317391A (en) 1990-02-14 1991-09-03 Chugai Seiyaku Kabushiki Kaisha Inhibitor of denatured ldl formation
FR2663850B1 (fr) 1990-07-02 1994-01-14 Gird Galderma Composition pharmaceutique ou cosmetique contenant en association un retinouide et un sterol.
EP0619116A3 (en) 1993-04-05 1994-11-23 Hoechst Japan Use of synthetic retinoids for osteopathy.
US5648385A (en) 1994-01-03 1997-07-15 Bristol-Myers Squibb Co. Retinoid-like compounds
US5849735A (en) 1995-01-17 1998-12-15 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
US5559248A (en) 1995-04-05 1996-09-24 Bristol-Myers Squibb Co. Retinoid-like heterocycles
AU693682B2 (en) 1995-04-10 1998-07-02 Taiho Pharmaceutical Co., Ltd. Cancerous metastasis inhibitor
JP3964478B2 (ja) 1995-06-30 2007-08-22 エーザイ・アール・アンド・ディー・マネジメント株式会社 ヘテロ環含有カルボン酸誘導体及びそれを含有する医薬
FR2739777B1 (fr) 1995-10-11 1997-11-14 Cird Galderma Ligand antagoniste rar-gamma ou agoniste rar-alpha en tant qu'inhibiteur d'apoptose
US5663357A (en) 1995-11-22 1997-09-02 Allergan Substituted heteroarylamides having retinoid-like biological activity
WO2000001679A1 (en) 1998-07-01 2000-01-13 Takeda Chemical Industries, Ltd. Retinoid-associated receptor regulators
US6245884B1 (en) 1998-10-16 2001-06-12 Vivian Y. H. Hook Secretases related to alzheimer's dementia
EP1514867A3 (en) 1998-10-22 2005-03-23 NeuroSearch A/S Substituted phenyl derivatives, their preparation and use
TW400614B (en) 1998-11-06 2000-08-01 United Microelectronics Corp The manufacture method of Shallow Trench Isolation(STI)
CN1225468C (zh) 2000-09-22 2005-11-02 全药工业株式会社 头孢烯化合物以及含有该化合物的esbl检测试剂
AU2002231098A1 (en) 2000-12-15 2002-06-24 Emory University Nonpeptide agonists and antagonists of vasopressin receptors
GB0103998D0 (en) 2001-02-19 2001-04-04 King S College London Method
US7105566B2 (en) * 2002-10-22 2006-09-12 Allergan, Inc. Methods of treatment during vascular procedures
US8367822B2 (en) 2003-09-22 2013-02-05 Enzo Therapeutics, Inc. Compositions and methods for bone formation and remodeling
KR100921173B1 (ko) * 2007-11-14 2009-10-13 (주)아모레퍼시픽 피부 내에서 히알루론산 생합성을 촉진시키는3,4,5-트리메톡시벤즈 아미드 유도체 화합물, 그 제조방법및 이를 함유하는 화장료 조성물
BRPI1013392A2 (pt) 2009-03-31 2016-03-29 Renascience Co Ltd inibidor do inibidor-1 do ativador do plasminogênio
GB0915196D0 (en) 2009-09-01 2009-10-07 King S College London Therapeutic compounds and their use
WO2012058378A1 (en) 2010-10-29 2012-05-03 Romark Laboratories L.C. Pharmaceutical compositions and methods of use of salicylanilides for treatment of hepatitis viruses

Also Published As

Publication number Publication date
GB0915196D0 (en) 2009-10-07
JP2013503819A (ja) 2013-02-04
MX2012002481A (es) 2012-03-26
IL218137A (en) 2016-06-30
US20160039747A1 (en) 2016-02-11
CA2771097C (en) 2019-01-15
NZ598331A (en) 2013-10-25
CA2771097A1 (en) 2011-03-10
AU2010291056B2 (en) 2016-01-28
CN102639487A (zh) 2012-08-15
EP2473479A1 (en) 2012-07-11
SG178480A1 (en) 2012-04-27
US20120149737A1 (en) 2012-06-14
JP5778675B2 (ja) 2015-09-16
US9447028B2 (en) 2016-09-20
AU2010291056A1 (en) 2012-03-15
ZA201201287B (en) 2013-05-29
IL218137A0 (en) 2012-06-28
WO2011027106A1 (en) 2011-03-10
BR112012004173A2 (pt) 2017-05-30

Similar Documents

Publication Publication Date Title
RU2475487C2 (ru) Имидазохинолины с иммуномодулирующими свойствами
RU2336275C2 (ru) Пиримидопроизводные, характеризующиеся антипролиферативной активностью, и фармацевтическая композиция
JP2002541245A5 (cg-RX-API-DMAC7.html)
JP2023521116A5 (cg-RX-API-DMAC7.html)
RU2351592C2 (ru) Производные тетрагидрохинолина и фармацевтическая композиция на их основе для лечения и профилактики вич-инфекции
RU2012144751A (ru) Гетероциклические соединения, эффективные для ингибирования киназы
RU2015106605A (ru) Соединения замещенных пиразолонов и способы использования
RU2007108861A (ru) Трифтометилзамещенные бензамиды в качестве ингибиторов киназ
RU2013108641A (ru) Способ лечения офтальмологических заболеваний с использованием соединений ингибиторов киназы в пролекарственных формах
RU2010136050A (ru) 2-аминохинолиновые производные для использования в качестве ингибиторов секретазы (васе)
RU2004122414A (ru) Цис-2,4,5-трифенилимидазолины и их применение для лечения опухолевых заболеваний
RU2006134003A (ru) Серосодержащие соединения, действующие как ингибиторы сериновой протеазы ns3 вируса гепатита с
JP2025514386A5 (cg-RX-API-DMAC7.html)
RU2008135690A (ru) Соединения и композиции в качестве ингибиторов протеинкиназы
RU2005117341A (ru) Пиримидиновые соединения, обладающие антипролиферативной активностью (ii)
RU2003120798A (ru) Новые производные n-(фенилсульфонил) глицина и их применение в терапии
RU2001130140A (ru) Производные адамантана
RU2012104244A (ru) Аналоги tofa, применимые при лечении дерматологических расстройств или состояний
JP2006503866A5 (cg-RX-API-DMAC7.html)
JP2017507122A5 (cg-RX-API-DMAC7.html)
RU2010117225A (ru) Аналоги хинолона и относящиеся к ним способы
RU2002123350A (ru) Дипептиднитрильные ингибиторы катепсина К
JP2005519908A5 (cg-RX-API-DMAC7.html)
RU2003128307A (ru) Азолы в качестве ингибиторов малонил-соа-декарбоксилазы, полезные в качестве модуляторов метаболиза
WO2006086705B1 (en) Substituted bis aryl and heteroaryl compounds as selective 5ht2a antagonists

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20150824